<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768287</url>
  </required_header>
  <id_info>
    <org_study_id>IB1001-01</org_study_id>
    <nct_id>NCT00768287</nct_id>
  </id_info>
  <brief_title>Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B</brief_title>
  <official_title>Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptevo BioTherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptevo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the safety (acute effects associated with infusions, and inhibitor development),
      pharmacokinetics (PK), and efficacy with respect to breakthrough bleeding during prophylaxis
      and with respect to control of hemorrhaging in both the prophylaxis and on demand groups of
      IB1001 in subjects with hemophilia B.

      Key Secondary Objectives:

      To evaluate the ability of IB1001 to provide coverage against bleeding under surgical
      circumstances; To evaluate the long-term safety and efficacy of IB1001
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Study Part 1: Randomized, double-blind, cross-over study of pharmacokinetics; Study Part 2: Non-randomized, open-label study of safety and efficacy; Surgical sub-study: Non-randomized, open-label study of safety and efficacy during major surgery</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study Part 1 only</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of Hemorrhage Control by Treatment Regimen</measure>
    <time_frame>Prophylaxis Group Duration of Treatment: 17.9 ± 9.6 months; On Demand Group Duration of Treatment: 15.9 ± 11.5 months</time_frame>
    <description>Subject rating of bleed control within 6 hours of the time bleeding has stopped:
Excellent: a dramatic response with abrupt pain relief and clear reduction in joint or hemorrhage site size;
Good: pain relief or reduction in hemorrhage site size that may have required an additional infusion for resolution;
Fair: probable or slight beneficial response usually requiring one or more additional infusions for resolution;
Poor: no improvement or condition worsens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (0-inf)</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (0-72 hr)</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration (Max)</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Steady State)</measure>
    <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
    <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleed Rate</measure>
    <time_frame>Prophylaxis Group Duration of Treatment: 17.9 ± 9.6 months; On Demand Group Duration of Treatment: 15.9 ± 11.5 months</time_frame>
    <description>Measure was assessed during the Treatment Study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood Loss During Surgery</measure>
    <time_frame>During the surgical procedure</time_frame>
    <description>Surgeon assessment of blood loss during the procedure using the following descriptors: less than expected, expected, or more than expected. Measure was assessed during Surgical Substudy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemostasis Following Surgery</measure>
    <time_frame>12 and 24 hours after surgery</time_frame>
    <description>Surgeon assessment of hemostasis at 12 and 24 hours after surgery using the following descriptors: superior, adequate, or poorly controlled. Measure was assessed during Surgical Substudy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Surgeries Requiring Blood Transfusions</measure>
    <time_frame>During the surgical procedure</time_frame>
    <description>Measure was assessed during Surgical Substudy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>IB1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>nonacog alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IB1001</intervention_name>
    <description>Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery</description>
    <arm_group_label>IB1001</arm_group_label>
    <other_name>Recombinant factor IX (rFIX)</other_name>
    <other_name>IXINITY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nonacog alfa</intervention_name>
    <description>Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa</description>
    <arm_group_label>nonacog alfa</arm_group_label>
    <other_name>Recombinant factor IX (rFIX)</other_name>
    <other_name>BeneFIX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must be willing to give written Institutional Review Board (IRB)/Independent
             Ethics Committee (IEC)-approved informed consent, make the required study visits, and
             follow instructions while enrolled in the study

          2. Severe (factor IX activity ≤2 U/dL) hemophilia B subjects on demand therapy with a
             minimum of 3 bleeding episodes over the preceding 6 months or 6 bleeding episodes over
             the preceding 12 months; subjects on prophylaxis with a bleeding pattern as above
             demonstrated prior to starting prophylaxis

          3. Immunocompetent (CD4 count &gt;400/mm3) and not receiving immune modulating or
             chemotherapeutic agents

          4. Previously treated patients with a minimum of 150 exposure days to a factor IX
             preparation

          5. Platelet count at least 150,000/mm3

          6. Liver function: alanine transaminase [ALT] and aspartate transaminase [AST] ≤2 times
             the upper limit of the normal range

          7. Total bilirubin ≤1.5 times the upper limit of the normal range

          8. Renal function: serum creatinine ≤1.25 times the upper limit of the normal range

          9. Willingness to participate in the trial for up to 12-15 months

         10. European Union (EU), Israel, and Canada: Age of at least 12 years and body weight of
             ≥40 kilograms to participate in any PK Study or the Surgical Sub-study [the Surgical
             Sub-study does not apply to the UK]; age of at least 12 years for the prophylaxis and
             on demand components of the Treatment Phase and Continuation Study

             United States (US): Age of at least 12 years and body weight of ≥40 kilograms to
             participate in any PK Study or the Surgical Sub-study; age of at least 5 years for the
             prophylaxis and on demand components of the Treatment Phase and Continuation Study

         11. Hemoglobin ≥7 g/dL at the time of the blood draw

        Exclusion Criteria:

          1. History of factor IX inhibitor ≥0.6 Bethesda units (BU)

          2. Existence of another coagulation disorder

          3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular
             coagulation (DIC)

          4. Use of an investigational drug within 30 days prior to study entry

          5. On medications that could impact hemostasis, such as aspirin

          6. History of poor compliance, a serious medical or social condition, or any other
             circumstance that, in the opinion of the investigator, would interfere with
             participation or compliance with the study protocol

          7. History of adverse reaction to either plasma-derived factor IX or recombinant factor
             IX that interfered with the subject's ability to treat bleeding episodes with a factor
             IX product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hemophilia Treatment Center of Orthopaedic Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine Pediatric Hematology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center-Pediatric Hematology Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Center for Bleeding and Clotting Disorder</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia Treatment Center of Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia and Thrombosis Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center-Houston, Gulf States Hemophilia &amp; Thrombophilia Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Traitement de l 'Hemophilie</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahyadri Specialty Hospital, Deccan Gymkhana</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Clinical Development Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Hemophilia Center-Sheba MC</name>
      <address>
        <city>Tel Hashomer</city>
        <state>Ramat Gan</state>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Careggi</name>
      <address>
        <city>Florence</city>
        <zip>I-50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milan</name>
      <address>
        <city>Milano</city>
        <zip>I-20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research</name>
      <address>
        <city>Warsaw</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Haemophilia Comprehensive Care Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S102JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Haemostasis and Thrombosis, Basingstoke and North Hampshire Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales Health Park</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF4 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Collins PW, Quon DVK, Makris M, Chowdary P, Kempton CL, Apte SJ, Ramanan MV, Hay CRM, Drobic B, Hua Y, Babinchak TJ, Gomperts ED. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2018 Jan;24(1):104-112. doi: 10.1111/hae.13324. Epub 2017 Aug 17.</citation>
    <PMID>28833808</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <results_first_submitted>March 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2018</results_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects could enter the study at any part and could leave at any time. Of the 77 subjects in the total study population, 32 entered during the PK part, 35 entered during the Treatment part, and 10 entered during the Surgical Substudy. Nine subjects participated only in one Part: 3 only in the PK study and 6 only in the Surgical Substudy</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PK: IB1001 First, Then Nonacog Alfa</title>
          <description>Pharmacokinetic Study: Randomized, double-blind, cross-over study</description>
        </group>
        <group group_id="P2">
          <title>PK: Nonacog Alfa First, Then IB1001</title>
          <description>Pharmacokinetic Study: Randomized, double-blind, cross-over study</description>
        </group>
        <group group_id="P3">
          <title>Repeat IB1001 PK</title>
          <description>Repeat Pharmacokinetic Study: Non-randomized, open-label study</description>
        </group>
        <group group_id="P4">
          <title>IB1001 Prophylaxis</title>
          <description>Treatment Study: Non-randomized, open-label study</description>
        </group>
        <group group_id="P5">
          <title>IB1001 On Demand</title>
          <description>Treatment Study: Non-randomized, open-label study</description>
        </group>
        <group group_id="P6">
          <title>IB1001 Surgical Substudy</title>
          <description>Surgical Substudy: Non-randomized, open-label study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pharmacokinetic Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Repeat Pharmacokinetic Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14">Eight subjects were part of the IB1001 first group; 6 were from the nonacog alfa first group.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="58">1 subject was not assigned a regimen at the start of the study.</participants>
                <participants group_id="P5" count="9">1 subject was not assigned a regimen at the start of the study.</participants>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="61">Subjects could switch treatment regimens. 3 subjects switched from On Demand to Prophylaxis.</participants>
                <participants group_id="P5" count="12">Subjects could switch treatment regimens. 3 subjects switched from Prophylaxis to On Demand.</participants>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Surgical Sub-study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="17">1 female subject was excluded from the efficacy analysis. She was included in the safety population.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IB1001 Safety Population</title>
          <description>Study Population exposed to at least one infusion of IB1001.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian/Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Degree of Hemorrhage Control by Treatment Regimen</title>
        <description>Subject rating of bleed control within 6 hours of the time bleeding has stopped:
Excellent: a dramatic response with abrupt pain relief and clear reduction in joint or hemorrhage site size;
Good: pain relief or reduction in hemorrhage site size that may have required an additional infusion for resolution;
Fair: probable or slight beneficial response usually requiring one or more additional infusions for resolution;
Poor: no improvement or condition worsens.</description>
        <time_frame>Prophylaxis Group Duration of Treatment: 17.9 ± 9.6 months; On Demand Group Duration of Treatment: 15.9 ± 11.5 months</time_frame>
        <population>The 68 patients in the Treatment Study (Part 2) were assigned to an initial treatment regimen as follows: prophylaxis (n=58), on demand (n=9), and unassigned (n=1). Patients were allowed to switch regimens during the course of the study. As a result 61 patients were treated with prophylaxis and 12 patients were treated on demand.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001 (On Demand)</title>
            <description>IB1001 50-100 IU/kg at the time of a bleeding episode</description>
          </group>
          <group group_id="O2">
            <title>IB1001 (Prophylaxis)</title>
            <description>IB1001 50-75 IU/kg twice a week</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Hemorrhage Control by Treatment Regimen</title>
          <description>Subject rating of bleed control within 6 hours of the time bleeding has stopped:
Excellent: a dramatic response with abrupt pain relief and clear reduction in joint or hemorrhage site size;
Good: pain relief or reduction in hemorrhage site size that may have required an additional infusion for resolution;
Fair: probable or slight beneficial response usually requiring one or more additional infusions for resolution;
Poor: no improvement or condition worsens.</description>
          <population>The 68 patients in the Treatment Study (Part 2) were assigned to an initial treatment regimen as follows: prophylaxis (n=58), on demand (n=9), and unassigned (n=1). Patients were allowed to switch regimens during the course of the study. As a result 61 patients were treated with prophylaxis and 12 patients were treated on demand.</population>
          <units>Bleeding Episodes</units>
          <param>Count of Units</param>
          <units_analyzed>Bleeding Episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Excellent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Rated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (0-inf)</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (0-inf)</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>IU*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1572.5" spread="451.5"/>
                    <measurement group_id="O2" value="1656.5" spread="468.6"/>
                    <measurement group_id="O3" value="1530.0" spread="435.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (0-72 hr)</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (0-72 hr)</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>IU*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1374.6" spread="356.4"/>
                    <measurement group_id="O2" value="1414.5" spread="339.4"/>
                    <measurement group_id="O3" value="1355.9" spread="381.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="6.9"/>
                    <measurement group_id="O2" value="26.4" spread="13.6"/>
                    <measurement group_id="O3" value="24.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration (Max)</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration (Max)</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>IU/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="16.6"/>
                    <measurement group_id="O2" value="72.8" spread="17.5"/>
                    <measurement group_id="O3" value="72.7" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>IU/dL per IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.21"/>
                    <measurement group_id="O2" value="0.94" spread="0.23"/>
                    <measurement group_id="O3" value="0.94" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" spread="6.4"/>
                    <measurement group_id="O2" value="35.4" spread="13.1"/>
                    <measurement group_id="O3" value="30.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>dL/kg*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" spread="0.013"/>
                    <measurement group_id="O2" value="0.050" spread="0.012"/>
                    <measurement group_id="O3" value="0.052" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Steady State)</title>
        <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
        <time_frame>Pre-infusion to 72 hours following infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001</title>
            <description>IB1001 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Nonacog Alfa</title>
            <description>nonacog alfa 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Repeat IB1001</title>
            <description>Repeat PK study of IB1001 75 ± 5 IU/kg 3.1 to 18.6 (median 5.8) months following initial PK study</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Steady State)</title>
          <description>Factor IX levels were assessed at the following time points: Pre-infusion, post-infusion at 30 min ± 5 min, 1 hour ± 5 min, 3 hours ± 30 min, 6 hours ± 1 hour, 9 hours ± 1 hour, 12 hours ± 2 hours, 24 hours ± 3 hours, 36 hours ± 3 hours, 48 hours ± 3 hours, 60 hours ± 3 hours, and 72 hours ± 3 hours.</description>
          <units>dL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.57"/>
                    <measurement group_id="O2" value="1.81" spread="0.57"/>
                    <measurement group_id="O3" value="1.85" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Bleed Rate</title>
        <description>Measure was assessed during the Treatment Study</description>
        <time_frame>Prophylaxis Group Duration of Treatment: 17.9 ± 9.6 months; On Demand Group Duration of Treatment: 15.9 ± 11.5 months</time_frame>
        <population>The 68 patients in the Treatment Study (Part 2) were assigned to an initial treatment regimen as follows: prophylaxis (n=58), on demand (n=9), and unassigned (n=1). Patients were allowed to switch regimens during the course of the study. As a result 61 patients were treated with prophylaxis and 12 patients were treated on demand.</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001 (On Demand)</title>
            <description>IB1001 50-100 IU/kg at the time of a bleeding episode</description>
          </group>
          <group group_id="O2">
            <title>IB1001 (Prophylaxis)</title>
            <description>IB1001 50-75 IU/kg twice a week</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleed Rate</title>
          <description>Measure was assessed during the Treatment Study</description>
          <population>The 68 patients in the Treatment Study (Part 2) were assigned to an initial treatment regimen as follows: prophylaxis (n=58), on demand (n=9), and unassigned (n=1). Patients were allowed to switch regimens during the course of the study. As a result 61 patients were treated with prophylaxis and 12 patients were treated on demand.</population>
          <units>Bleeds/year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.10" lower_limit="6.6" upper_limit="23.7"/>
                    <measurement group_id="O2" value="1.52" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood Loss During Surgery</title>
        <description>Surgeon assessment of blood loss during the procedure using the following descriptors: less than expected, expected, or more than expected. Measure was assessed during Surgical Substudy.</description>
        <time_frame>During the surgical procedure</time_frame>
        <population>Major surgeries include synovectomy, knee or hip replacement, total tooth extraction, surgery for intracranial hemorrhage, radial head excision, arthrodesis, ankle surgery, abdominal surgery, prostatectomy, or surgery for major muscle bleed repair</population>
        <group_list>
          <group group_id="O1">
            <title>IB1001 - Surgical Substudy</title>
            <description>IB1001 Bolus Regimen: 120 IU/kg prior to start of procedure, followed by 60 IU/kg 12 hours after the first infusion, and up to 120 IU/kg 24 hours after the first infusion. Bolus infusions continue every 12 hours for a minimum of 3 days; or
IB1001 Continuous Infusion Regimen: IB1001 infused at a target range of 70% to 110% for a minimum of 3 days post-procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Loss During Surgery</title>
          <description>Surgeon assessment of blood loss during the procedure using the following descriptors: less than expected, expected, or more than expected. Measure was assessed during Surgical Substudy.</description>
          <population>Major surgeries include synovectomy, knee or hip replacement, total tooth extraction, surgery for intracranial hemorrhage, radial head excision, arthrodesis, ankle surgery, abdominal surgery, prostatectomy, or surgery for major muscle bleed repair</population>
          <units>Major surgeries</units>
          <param>Count of Units</param>
          <units_analyzed>Major surgeries</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Major surgeries</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than expected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Expected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than expected</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hemostasis Following Surgery</title>
        <description>Surgeon assessment of hemostasis at 12 and 24 hours after surgery using the following descriptors: superior, adequate, or poorly controlled. Measure was assessed during Surgical Substudy.</description>
        <time_frame>12 and 24 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001 (12 Hours) - Surgical Substudy</title>
            <description>Hemostasis 12 hours following surgery;
IB1001 Bolus Regimen: 120 IU/kg prior to start of procedure, followed by 60 IU/kg 12 hours after the first infusion, and up to 120 IU/kg 24 hours after the first infusion. Bolus infusions would continue every 12 hours for a minimum of 3 days; or
IB1001 Continuous Infusion Regimen: IB1001 infused at a target range of 70% to 110% for a minimum of 3 days post-procedure.</description>
          </group>
          <group group_id="O2">
            <title>IB1001 (24 Hours) - Surgical Substudy</title>
            <description>Hemostasis 24 hours following surgery;
IB1001 Bolus Regimen: 120 IU/kg prior to start of procedure, followed by 60 IU/kg 12 hours after the first infusion, and up to 120 IU/kg 24 hours after the first infusion. Bolus infusions would continue every 12 hours for a minimum of 3 days; or
IB1001 Continuous Infusion Regimen: IB1001 infused at a target range of 70% to 110% for a minimum of 3 days post-procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis Following Surgery</title>
          <description>Surgeon assessment of hemostasis at 12 and 24 hours after surgery using the following descriptors: superior, adequate, or poorly controlled. Measure was assessed during Surgical Substudy.</description>
          <units>Major surgeries</units>
          <param>Count of Units</param>
          <units_analyzed>Major surgeries</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Major surgeries</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Superior</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poorly Controlled</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Surgeries Requiring Blood Transfusions</title>
        <description>Measure was assessed during Surgical Substudy.</description>
        <time_frame>During the surgical procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IB1001 - Surgical Substudy</title>
            <description>IB1001 Bolus Regimen: 120 IU/kg prior to start of procedure, followed by 60 IU/kg 12 hours after the first infusion, and up to 120 IU/kg 24 hours after the first infusion. Bolus infusions would continue every 12 hours for a minimum of 3 days; or
IB1001 Continuous Infusion Regimen: IB1001 infused at a target range of 70% to 110% for a minimum of 3 days post-procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Surgeries Requiring Blood Transfusions</title>
          <description>Measure was assessed during Surgical Substudy.</description>
          <units>Major surgeries</units>
          <param>Count of Units</param>
          <units_analyzed>Major surgeries</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Major surgeries</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Blood Transfusion Required</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Blood Transfusion Required</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IB1001 Safety Population</title>
          <description>Adverse Events were only analyzed for the IB1001 safety population; they were not collected per intervention. The safety population is defined as all subjects who received at least one dose of IB1001 in any part of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <description>Deemed unrelated to IB1001</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dairrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="13" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Schaaf</name_or_title>
      <organization>Aptevo Therapeutics</organization>
      <phone>206-859-6655</phone>
      <email>schaafd@apvo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

